BICO.ST
BICO Group AB (publ) [BICO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BICO.ST Stock Summary
Top 10 Correlated Stocks
BICO.ST
In the News
BICO.ST Financial details
Company Rating
Neutral
Market Cap
3.04B
Income
-1.99B
Revenue
2.3B
Book val./share
83.59
Cash/share
7.96
Dividend
-
Dividend %
-
Employees
880
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-1.95
Forward P/E
-
PEG
-0.03
P/S
1.65
P/B
0.66
P/C
5.56
P/FCF
-8.73
Quick Ratio
1.64
Current Ratio
2.39
Debt / Equity
0.32
LT Debt / Equity
0.3
-
-
EPS (TTM)
-29.48
EPS next Y
-
EPS next Q
-
EPS this Y
224.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
118.14%
Revenue Q/Q
8.52%
EPS Q/Q
-92.14%
-
-
-
-
SMA20
2.33%
SMA50
-22.81%
SMA100
-13.73%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-31%
ROC
-0.23%
Gross Margin
75%
Oper. Margin
-80%
Profit Margin
-86%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
23.38-72.3
52W High
-38.56%
52W Low
+92.35%
RSI
51
Rel Volume
0.44
Avg Volume
354.92K
Volume
156.95K
Perf Week
-0.58%
Perf Month
4.96%
Perf Quarter
56.49%
Perf Half Y
81.16%
-
-
-
-
Beta
2.339
-
-
Volatility
0.96%, 2.35%
Prev Close
-1.73%
Price
44.24
Change
-1.86%
BICO.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-08-31 | 2019-08-31 | 2020-08-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.47 | 3.02 | 4.19 | 21.96 | 34.8 | |
| Net income per share | 0.04 | 0.02 | -1.47 | -4 | -12.99 | |
| Operating cash flow per share | -0.4 | -0.45 | -1.7 | -7.15 | -4.19 | |
| Free cash flow per share | -1.02 | -1.48 | -3.65 | -11.81 | -12.42 | |
| Cash per share | 4.42 | 3.13 | 23.57 | 25.76 | 14.38 | |
| Book value per share | 6.03 | 15.75 | 35.92 | 118.29 | 107.31 | |
| Tangible book value per share | 5.05 | 4.58 | 36.05 | 4.89 | 3.41 | |
| Share holders equity per share | 6.03 | 15.75 | 35.92 | 118.29 | 107.31 | |
| Interest debt per share | 0.02 | 0.02 | 1.65 | 29.09 | 30.32 | |
| Market cap | 1.13B | 2.31B | 6.97B | 15.91B | 6.81B | |
| Enterprise value | 1.1B | 2.27B | 6.22B | 17.03B | 7.74B | |
| P/E ratio | 952.31 | 3.98K | -112.62 | -69.41 | -8.15 | |
| Price to sales ratio | 24.85 | 21.93 | 39.42 | 12.65 | 3.04 | |
| POCF ratio | -91.87 | -146.2 | -97.05 | -38.88 | -25.27 | |
| PFCF ratio | -35.82 | -44.85 | -45.22 | -23.53 | -8.52 | |
| P/B Ratio | 6.05 | 4.21 | 4.59 | 2.35 | 0.99 | |
| PTB ratio | 6.05 | 4.21 | 4.59 | 2.35 | 0.99 | |
| EV to sales | 24.35 | 21.56 | 35.2 | 13.55 | 3.45 | |
| Enterprise value over EBITDA | 296.97 | 390.55 | -157.55 | 535.66 | 24 | |
| EV to operating cash flow | -90.04 | -143.72 | -86.66 | -41.63 | -28.72 | |
| EV to free cash flow | -35.1 | -44.09 | -40.38 | -25.19 | -9.68 | |
| Earnings yield | 0 | 0 | -0.01 | -0.01 | -0.12 | |
| Free cash flow yield | -0.03 | -0.02 | -0.02 | -0.04 | -0.12 | |
| Debt to equity | 0 | 0 | 0.04 | 0.24 | 0.27 | |
| Debt to assets | 0 | 0 | 0.04 | 0.16 | 0.18 | |
| Net debt to EBITDA | -6.03 | -6.74 | 18.89 | 35.39 | 2.88 | |
| Current ratio | 19.69 | 5.45 | 17.82 | 3.63 | 2.59 | |
| Interest coverage | 14.88 | -33.52 | -9.07 | -2.7 | -6.3 | |
| Income quality | -32.97 | 4.21 | 0.98 | 1.92 | 0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.36 | 0.44 | 0.48 | 0.34 | 0.32 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.16 | 0.65 | 0.26 | 0.67 | 0.66 | |
| Capex to operating cash flow | 1.56 | 2.26 | 1.15 | 0.65 | 1.97 | |
| Capex to revenue | -0.42 | -0.34 | -0.47 | -0.21 | -0.24 | |
| Capex to depreciation | -7.31 | -5.04 | -3.11 | -1.39 | -0.56 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0.01 | 0.02 | |
| Graham number | 2.28 | 2.43 | 34.41 | 103.21 | 177.08 | |
| ROIC | 0 | -0.07 | -0.03 | -0.02 | -0.07 | |
| Return on tangible assets | 0.01 | 0 | -0.05 | -0.07 | -0.24 | |
| Graham Net | 4.72 | 3.31 | 22.5 | -22.99 | -20.65 | |
| Working capital | 153.62M | 162.28M | 1.06B | 1.92B | 1.5B | |
| Tangible asset value | 155.75M | 159.79M | 1.09B | 280M | 219.3M | |
| Net current asset value | 153.02M | 145.29M | 996.97M | -297.9M | -827.6M | |
| Invested capital | 0 | 0 | 0.04 | 0.24 | 0.27 | |
| Average receivables | 10.66M | 41.15M | 70.94M | 40.46M | 509.3M | |
| Average payables | 3.25M | 8.93M | 12.24M | 69.74M | 130.85M | |
| Average inventory | 3.16M | 16.34M | 35.12M | 181.08M | 406.85M | |
| Days sales outstanding | 171.69 | 211.04 | 167.05 | 0 | 166.01 | |
| Days payables outstanding | 237.27 | 365.44 | 287.36 | 184.79 | 118.36 | |
| Days of inventory on hand | 253.44 | 742.56 | 1.15K | 458.9 | 440.16 | |
| Receivables turnover | 2.13 | 1.73 | 2.18 | 0 | 2.2 | |
| Payables turnover | 1.54 | 1 | 1.27 | 1.98 | 3.08 | |
| Inventory turnover | 1.44 | 0.49 | 0.32 | 0.8 | 0.83 | |
| ROE | 0.01 | 0 | -0.04 | -0.03 | -0.12 | |
| Capex per share | -0.62 | -1.02 | -1.95 | -4.66 | -8.23 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.59 | 10.52 | 7.1 | 7.67 | 8.32 | |
| Net income per share | 1.04 | -14.07 | -1.68 | -12.73 | -1 | |
| Operating cash flow per share | -0.24 | -1.08 | 0.86 | -0.68 | 0.05 | |
| Free cash flow per share | -2.46 | -2.89 | -0.68 | -1.92 | -0.94 | |
| Cash per share | 10.74 | 14.44 | 12.18 | 9.79 | 7.96 | |
| Book value per share | 114.41 | 107.75 | 96.72 | 85.18 | 83.59 | |
| Tangible book value per share | 114.89 | 3.42 | 97.1 | -0.64 | -0.93 | |
| Share holders equity per share | 114.41 | 107.75 | 96.72 | 85.18 | 83.59 | |
| Interest debt per share | 29.12 | 28.78 | 27.12 | 27.25 | 26.97 | |
| Market cap | 1.9B | 6.78B | 3.82B | 2.75B | 2.12B | |
| Enterprise value | 3.28B | 7.71B | 4.84B | 3.97B | 3.44B | |
| P/E ratio | 7.15 | -1.88 | -8.07 | -0.77 | -7.51 | |
| Price to sales ratio | 3.45 | 10.06 | 7.64 | 5.09 | 3.61 | |
| POCF ratio | -121.76 | -98.12 | 63.3 | -57.72 | 589.3 | |
| PFCF ratio | -12.06 | -36.65 | -79.81 | -20.29 | -31.9 | |
| P/B Ratio | 0.26 | 0.98 | 0.56 | 0.46 | 0.36 | |
| PTB ratio | 0.26 | 0.98 | 0.56 | 0.46 | 0.36 | |
| EV to sales | 5.95 | 11.43 | 9.66 | 7.33 | 5.85 | |
| Enterprise value over EBITDA | 12.59 | -37.8 | -428.14 | -6.8 | 39.46 | |
| EV to operating cash flow | -210.05 | -111.55 | 80.1 | -83.17 | 954.74 | |
| EV to free cash flow | -20.81 | -41.67 | -101 | -29.24 | -51.69 | |
| Earnings yield | 0.03 | -0.13 | -0.03 | -0.33 | -0.03 | |
| Free cash flow yield | -0.08 | -0.03 | -0.01 | -0.05 | -0.03 | |
| Debt to equity | 0.25 | 0.27 | 0.27 | 0.32 | 0.32 | |
| Debt to assets | 0.17 | 0.18 | 0.19 | 0.21 | 0.21 | |
| Net debt to EBITDA | 5.29 | -4.55 | -89.81 | -2.08 | 15.1 | |
| Current ratio | 2.08 | 2.59 | 2.56 | 2.29 | 2.39 | |
| Interest coverage | 7.8 | 83.25 | -2.63 | -51.1 | -2.43 | |
| Income quality | -0.1 | 0.07 | -0.46 | 0.06 | -0.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.31 | 0.29 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.7 | 0.66 | 0.67 | 0.67 | 0.68 | |
| Capex to operating cash flow | 9.1 | 1.68 | -1.79 | 1.84 | -19.47 | |
| Capex to revenue | -0.26 | -0.17 | -0.22 | -0.16 | -0.12 | |
| Capex to depreciation | -1.86 | -0.16 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 51.65 | 184.7 | 60.45 | 156.18 | 43.38 | |
| ROIC | 0.01 | -0.08 | -0.01 | -0.12 | -0.01 | |
| Return on tangible assets | 0.02 | -0.26 | -0.04 | -0.3 | -0.02 | |
| Graham Net | -29.32 | -20.74 | -21.66 | -21.15 | -21.22 | |
| Working capital | 1.13B | 1.5B | 1.34B | 1.2B | 1.17B | |
| Tangible asset value | -233.3M | 219.3M | 144.2M | -45.2M | -65.6M | |
| Net current asset value | -1.26B | -827.6M | -985.4M | -945.8M | -915.1M | |
| Invested capital | 0.25 | 0.27 | 0.27 | 0.32 | 0.32 | |
| Average receivables | 740M | 897.3M | 862.1M | 763.65M | 823.85M | |
| Average payables | 165.65M | 148.45M | 139.85M | 148.9M | 144.2M | |
| Average inventory | 523.25M | 525M | 519.7M | 547.85M | 527.35M | |
| Days sales outstanding | 126.84 | 135.99 | 126.83 | 136.67 | 126.6 | |
| Days payables outstanding | 171.94 | 83.05 | 118.95 | 80.3 | 78.44 | |
| Days of inventory on hand | 582.8 | 308.83 | 441.75 | 292.75 | 287.83 | |
| Receivables turnover | 0.71 | 0.66 | 0.71 | 0.66 | 0.71 | |
| Payables turnover | 0.52 | 1.08 | 0.76 | 1.12 | 1.15 | |
| Inventory turnover | 0.15 | 0.29 | 0.2 | 0.31 | 0.31 | |
| ROE | 0.01 | -0.13 | -0.02 | -0.15 | -0.01 | |
| Capex per share | -2.21 | -1.81 | -1.53 | -1.25 | -0.99 |
BICO.ST Frequently Asked Questions
What is BICO Group AB (publ) stock symbol ?
BICO Group AB (publ) is a SE stock and trading under the symbol BICO.ST
What is BICO Group AB (publ) stock quote today ?
BICO Group AB (publ) stock price is $44.24 today.
Is BICO Group AB (publ) stock public?
Yes, BICO Group AB (publ) is a publicly traded company.
Company Profile
- Volume Average 354.92K
- Market Capitalization 3.04B
- Employee 880
- CEO Ms. Maria Forss
- Headquarters Gothenburg,SE
- IPO Date 2016-11-03
-
Website
https://bico.com 
BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
